Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
RESEARCH TOOLSreports
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.08Last Year’s EPS
0.26Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -25.79%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the TSHA-102 program, regulatory progress, a strong safety profile, and financial stability, despite an increase in R&D expenses. The overall sentiment is positive due to the outweighed highlights.Company Guidance
During the Taysha Gene Therapies Q3 2024 earnings call, the guidance provided highlighted several key metrics and strategic updates. The company reported a net loss of $25.5 million, or $0.10 per share, compared to a net loss of $117.1 million, or $0.93 per share, in the same quarter of 2023. Research and development expenses increased to $14.9 million, driven by GMP batch activities and higher R&D headcount, while general and administrative expenses decreased to $7.9 million. Taysha reiterated its financial outlook, with $157.7 million in cash and cash equivalents, expected to support operations into Q4 2026. The management also discussed the clinical progress of TSHA-102 for Rett syndrome, including promising safety and efficacy data from their ongoing REVEAL trials, and highlighted plans to report longer-term data in the first half of 2025. Regulatory engagements have been constructive, with recent FDA meetings advancing discussions on trial design and endpoints, leveraging the RMAT designation to expedite development.Progress in TSHA-102 Clinical Development
Significant progress was made in the TSHA-102 program for Rett syndrome, including regulatory milestones, clinical data supporting safety, and continued enrollment in high-dose cohorts.
Regulatory Advancements with FDA
Completed Type B meetings with FDA, gaining approval for the pivotal TSHA-102 product use in trials and aligning on a regulatory pathway using the RMAT mechanism.
Encouraging Safety Profile
High-dose TSHA-102 continued to show a favorable safety profile with no serious adverse events reported in both adolescent/adult and pediatric trials.
Financial Stability
Taysha reported cash and cash equivalents of $157.7 million, expected to support operations into the fourth quarter of 2026.
Reduction in Net Loss
Net loss for Q3 2024 was $25.5 million, a significant reduction from $117.1 million in Q3 2023, primarily due to non-cash adjustments.
---
TSHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $2.21 | $2.27 | +2.71% |
| Aug 12, 2024 | $2.09 | $2.04 | -2.39% |
| May 14, 2024 | $2.57 | $3.11 | +21.01% |
| Mar 19, 2024 | $2.25 | $2.96 | +31.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Taysha Gene Therapies (TSHA) report earnings?
Taysha Gene Therapies (TSHA) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Taysha Gene Therapies (TSHA) earnings time?
Taysha Gene Therapies (TSHA) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSHA EPS forecast?
TSHA EPS forecast for the fiscal quarter 2024 (Q4) is -0.08.
---